Glaxosmithkline Pharmaceuticals is currently trading at Rs. 3750.00, up by 13.05 points or 0.35% from its previous closing of Rs. 3736.95 on the BSE.
The scrip opened at Rs. 3748.00 and has touched a high and low of Rs. 3774.00 and Rs. 3720.00 respectively. So far 560 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3825.00 on 05-Aug-2015 and a 52 week low of Rs. 2965.65 on 27-Apr-2015.
Last one week high and low of the scrip stood at Rs. 3773.90 and Rs. 3599.00 respectively. The current market cap of the company is Rs. 31714.50 crore.
The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 11.74% and 13.26% respectively.
GlaxoSmithKline Pharmaceuticals is reportedly looking at launching two or three combination vaccines in India in the near future, to address a host of paediatric disease. The company is also organizing programmes to spread awareness about the need of vaccination among public.
The company is expected to launch a four-antigen, a five-antigen and a six-antigen combination to cover several disease in a single vaccine. Various paediatric disease vaccinations including diphtheria, pertussis (whooping cough), and tetanus (DPT), Hepatitis B and Polio are to be addressed through these combinations.
GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: